共 45 条
- [31] Phase I/II study of haploidentical stem cell transplantation with early transfer of highly purified donor CD56+CD3-NK cells as treatment option for refractory AMLBONE MARROW TRANSPLANTATION, 2010, 45 : S78 - S79Friedrichs, B.Basara, N.Nogai, A.Notter, M.Gentilini, C.Pfrepper, C.Niederwieser, D.Thiel, E.Uharek, L.
- [32] Mizoribine in living donor kidney transplantation: Twenty four-week results of a single center, pre-randomized, open-label, prospective, comparative, phase III studyTRANSPLANTATION, 1999, 67 (07) : S154 - S154Cho, DKPark, SHKim, JCKim, CDBaek, MYKim, SJKim, JHKim, SHKwon, THKim, YL
- [33] Phase 2 Study of Allogeneic Stem Cell Transplantation (ASCT) From Matched Related Donor (MRD) In Patients Older Than 55 Years After Reduced Intensity Conditioning (RIC) Associating Fludarabine, Intravenous Busulfan and Rabbit ThymoglobulinBLOOD, 2010, 116 (21) : 565 - 566Blaise, DidierMohty, MohamadBoher, Jean MarieMilpied, NoelFegueux, NathalieSirvent, AnneFurst, SabineMichallet, MauricetteEl Cheikh, JeanCastagna, LucaChevallier, PatriceBay, Jacques-OlivierCahn, Jean-YvesGuillaume, ThierryBouabdallah, RedaVey, NorbertTabrizi, RezaChabannon, ChristianFaucher, Catherine
- [34] A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. (vol 115, pg 1098, 2010)BLOOD, 2010, 115 (21) : 4318 - 4318Rodriguez, R.Nakamura, R.Palmer, J. M.
- [35] Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III StudyBLOOD, 2022, 140 : 2126 - 2129Niederwieser, DietgerHasenclever, DirkBerdel, Wolfgang E.Biemond, Bart J.Al-Ali, Haifa KathrinChalandon, YvesVan Gelder, MichelJunghanss, ChristianGahrton, GoestaHaenel, MathiasHehlmann, RudigerHeinicke, ThomasHochhaus, AndreasIacobelli, SimonaKooy, Rien van MarwijkKroger, NicolausJanssen, Jeroen J. W. M.Jentzsch, MadlenBreywisch, FrankMohty, MohamadMasouridi-Levrat, StavroulaOssenkoppele, GertPassweg, JakobPoenisch, WolframSchetelig, JohannesSchliemann, ChristophSchwind, SebastianStelljes, MatthiasValk, Peter J. M.Lowenberg, BobCornelissen, Jan J.
- [36] Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 StudyBLOOD, 2014, 124 (21)Bonini, ChiaraCiceri, FabioNagler, ArnonYannaki, EvangeliaStanghellini, Maria Teresa LupoOliveira, GiacomoBondanza, AttilioVago, LucaGreco, RaffaellaPeccatori, JacopoOlovarria, EduardoMischak-Weissinger, Eva M.Stadler, MichaelBunjes, DonaldNiederwieser, DietgerUharek, LutzBethge, Wolfgang A.DiPersio, John F.Donato, Michele L.Pecora, Andrew L.Colombi, ScialiniAntonio, LambiaseBordignon, Claudio
- [37] Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet)FRONTIERS IN PEDIATRICS, 2023, 11Moreno, CeliaRamos-Elbal, EduardoVelasco, PabloAguilar, YurenaMartinez, Berta GonzaalezFuentes, CarolinaMolinos, AguedaGuerra-Garcia, PilarPalomo, PilarVerdu, JaimePedroso, Rosa Maria AdanVagace, Jose ManuelLopez-Duarte, MonicaRegueiro, AlexandraTasso, MariaDapena, Jose LuisSalinas, Jose AntonioNavarro, SamuelBautista, FranciscoLassaletta, AlvaroLendinez, FranciscoRives, SusanaPascual, AntoniaRodriguez, AntoniaPerez-Hurtado, Jose MariaFernandez, Jose MariaPerez-Martinez, AntonioGonzalez-Vicent, Martade Heredia, Cristina DiazFuster, Jose Luis
- [38] Randomized Phase II Trial Comparing Cyclosporine (CSP) and Tacrolimus (TAC). for Methotrexate (MTX)-Free Graft-Versus-Host Disease (GVHD) Prophylaxis after Allogeneic Transplantation from a Matched Related Donor (MRD) with a Reduced-Intensity Regimen Containing Cladribine and BusulfanBLOOD, 2008, 112 (11) : 427 - 428Kim, Sung-WonFukuda, TakahiroHagiwara, ShotaroKomatsu, TsunehikoGoto, TetsuyaUeda, YasunoriIto, ToshiroHino, MasayukiSunami, KazutakaTanosaki, RyujiMori, Shin-ichiroKami, MasahiroTajima, KinukoTakaue, Yoichi
- [39] Allogeneic Stem Cell Transplantation From Matched Related Donor in Patients Over the Age of 55 Years: A Prospective Multicenter Phase II Study of a Reduced Intensity Conditioning Associating Fludarabin-IV Busulfan and ThymoglobulinBLOOD, 2011, 118 (21) : 851 - 852Blaise, DidierMohty, MohamadMilpied, NoelLecorroller, Anne GaelleFegueux, NathalieFurst, SabineChevallier, PatriceTabrizi, RezaMichallet, MauricetteCahn, Jean YvesSirvent, AnneBay, Jacques-OlivierEl Cheikh, JeanFaucher, CatherineCrocchiolo, RobertoBoyer-Chamard, AgnesCastagna, LucaBoher, Jean Marie
- [40] TK007 phase II study final analysis. Genetically modified donor lymphocytes abate transplant related mortality and increase leukaemia-free survival providing early immune reconstitution after haploidentical haematopoietic stem cell transplantationBONE MARROW TRANSPLANTATION, 2008, 41 : S55 - S56Stanghellini, M. T. LupoCiceri, F.Bonini, C.Bondanza, A.Traversari, C.Toma, S.Salomoni, M.Turchetto, L.Colombi, S.Bernardi, M.Peccatori, J.Pescarollo, A.Servida, P.Magnani, Z.Perna, S. K.Valtolina, V.Crippa, F.Callegaro, L.Spoldi, E.Fleischhauer, K.Ponzoni, M.Vago, L.Santoro, A.Todisco, E.Apperley, J.Slavin, S.Weissinger, E.Hertenstein, B.Bregni, M.Stampino, C. GalloBruzzi, P.Bordignon, C.